


UK Interim Clinical Commissioning Policy: Therapies for symptomatic non-hospitalised patients with COVID-19

Consider access to this clinical pathway for patients under the following conditions:


- Onset of symptoms of COVID-19 within the last 5 days (for nirmatrelvir/ritonavir¹, sotrovimab and molnupiravir) or 7 days (for remdesivir), remains symptomatic and with no signs of clinical recovery
- SARS-CoV-2 infection is confirmed by either lateral flow test or PCR (registered via gov.uk or NHS 119)
- The patient is a member of a 'highest' risk group (as defined in the Department of Health and Social Care commissioned Independent Advisory Group report)
- The patient is not hospitalised for COVID-19 and is not requiring new supplemental oxygen specifically for the management of COVID-19 symptoms

Consider the clinical suitability of antiviral or neutralising monoclonal antibody. Nirmatrelvir/ritonavir and sotrovimab are first-line options and remdesivir is second-line. Molnupiravir should be considered a third-line treatment option. (see page 2 for further information on choosing between antiviral and nMAB).

Antiviral Pathway



nMAB Pathway



¹ May also be known as Paxlovid
² Treatment commencement may be extended up to a maximum of 7 days from symptom onset if clinically indicated (off-label)
³ Nirmatrelvir/ritonavir may be considered in non-hospitalised patients with stage 3 CKD, if providers can assure themselves that the required dose modification can be delivered safely. See the Summary of Product Characteristics and the section on dosing in the policy for more information.
⁴ See Specialist Pharmacy Service (SPS) guidance for nirmatrelvir/ritonavir and University of Liverpool COVID-19 Drug Interactions checker
⁵ Patient-specific factors could include needle phobia and inability to attend for intravenous treatment (for sotrovimab and remdesivir) or swallowing difficulties with oral medications (nirmatrelvir/ritonavir and molnupiravir)
⁶ Please see remdesivir specific exclusion criteria in the clinical commissioning policy
Clinicians are encouraged to proactively support recruitment into trials developing further evidence in the treatment of COVID-19

Clinical Guide: Therapy characteristics when deciding on treatment choice

Use this guide to assist in decision making on which therapeutic option to use:

- Three products have similar relative risk reduction of reducing hospitalisation: nirmatrelvir/ritonavir, remdesivir; and sotrovimab
- Molnupiravir has a substantially lower level of efficacy - reserve when the others cannot be used
- Medicines availability will be monitored nationally and regionally, so unless otherwise directed do not consider supply issues in your decision making

Nirmatrelvir/ritonavir (Paxlovid)	Remdesivir (Veklury)	Sotrovimab (Xevudy)
Antiviral (dual therapy)	Antiviral (monotherapy)	Neutralising monoclonal antibody
Administered orally : 3 tablets twice a day for 5 days	Administered intravenously : one infusion every 24 hours for 3 days	Administered intravenously : single infusion
Adults only (aged 18 years and over)	Adults and adolescents (aged 12 years and over and weighing at least 40kg)	Adults and adolescents (aged 12 years and over and weighing at least 40kg)
Evidence based on treatment within 5 days of symptom onset	Evidence based on treatment within 7 days of symptom onset	Evidence based on treatment within 5 days of symptom onset
Not recommended in pregnancy	May be used in pregnancy where benefits of treatment outweigh risks	May be used in pregnancy although there is no safety data available
Breast-feeding should be discontinued during treatment and for 7 days after last dose	No specific advice on discontinuation of breast-feeding during treatment	No specific advice on discontinuation of breast-feeding during treatment
Contraindicated in severe liver and kidney disease	Not recommended in individuals with ALT ≥ 5 times the upper limit of normal or eGFR < 30 ml/min	No dose adjustment recommended in liver or renal impairment*
Multiple significant drug-drug interactions (see SPS guidance)	No significant drug-drug interactions	No significant drug-drug interactions
88% Relative Risk Reduction of hospitalisation	87% Relative Risk Reduction of hospitalisation	85% Relative Risk Reduction of hospitalisation

Molnupiravir (Lagevrio)	
Antiviral (monotherapy)	Breast-feeding should be discontinued during treatment and for 4 days after last dose
Administered orally : 4 capsules twice a day for 5 days	May be used in severe liver and kidney disease (no dose adjustment recommended)
Adults only (aged 18 years and over)	No significant drug-drug interactions
Not recommended in pregnancy	
30% Relative Risk Reduction of hospitalisation	

For the key publications of trial results and licence click here

Nirmatrelvir/ritonavir
NEJM Feb 2022

Nirmatrelvir/
ritonavir
SmPC

Remdesivir
NEJM Dec 2021

Remdesivir
SmPC

Sotrovimab
NEJM Nov 2021

Sotrovimab
SmPC

Molnupiravir
NEJM Dec 2021

Molnupiravir
SmPC

*there are limited/no data on the use of sotrovimab in patients with a creatinine clearance of < 30 ml/min/1.73m² and those with severe elevations ALT (5 - < 10 x upper limit of normal)

Clinical Guide: Specialty advice for 'highest-risk' cohorts

Specialty-specific advice on the management of patients within each of the highest-risk cohorts (particularly around the use of nirmatrelvir/ritonavir) may be found in the table below. Contact your local specialist team for further guidance on issues not covered by this advice.

Cohort	Advice/guidance
Liver disease	Nirmatrelvir/ritonavir should not be administered to patients with advanced decompensated cirrhosis. Such patients can be identified by questioning or review of medical records. Patients should be asked if they have ever been admitted to hospital with liver disease and if they are currently receiving regular ascitic drainage. A positive response is a contraindication to nirmatrelvir/ritonavir. If blood tests are available a bilirubin >50 at any time is a contraindication to nirmatrelvir/ritonavir, if the jaundice is due to liver disease. Patients receiving rifaximin (only used in very advanced liver disease) should not receive nirmatrelvir/ritonavir.
Solid organ transplant (non-renal)	Nirmatrelvir/ritonavir is currently contraindicated in both Solid Organ and Islet Transplant recipients due to significant harmful drug interactions especially anti-rejection medication. These patients should be triaged to receive sotrovimab.
Renal disease (including renal transplant)	Currently nirmatrelvir/ritonavir is not indicated in the majority of at-risk individuals with renal disease, due to lack of dosing information or drug interactions. These include patients with CKD stage 4 and 5, including those on dialysis, and in transplant patients due to interactions with immunosuppressive therapy. Nirmatrelvir/ritonavir requires dose modification in people with CKD stage 3 (see product information). When nMABs are not indicated or available, clinicians can discuss alternative treatment options such as remdesivir with renal provider clinicians. Remdesivir may be used in patients with an eGFR of $\geq 30\text{ml/min/1.73m}^2$ and in some patients on haemodialysis (discuss with renal clinicians for further guidance).
Solid cancer (including metastases); Haematological disease (including non-malignant conditions)	Specialist cancer and haematology teams are encouraged to establish a central provider email account to receive queries from clinicians treating patients with COVID-19 with antivirals and/or nMABs. For patients who are receiving SACT or complex supportive care for malignancy or stem cell transplantation, please ask whether the patient has already been contacted or reviewed by their specialist haematology/oncology/bone marrow transplant team. If the patient has not already been in contact with their specialist, please establish the location of the provider and consider referral to the respective specialist team via the central provider email where available. Please ask the patient to have details of their current medication available for any following consultation.
Rare neurological conditions	There are no specific needs for specialist neurology services to prescribe nirmatrelvir/ritonavir, though care should be taken with those who have difficulty swallowing or have supported feeding, and for those with behavioural or psychiatric concerns. If a patient is identified as eligible for nirmatrelvir/ritonavir due to neurology risk factors then ask about swallowing difficulties. Disease-specific advice is as follows: Multiple Sclerosis (MS) <ul style="list-style-type: none"> In addition to the medicines listed in the SPS guidance, avoid concurrent use of nirmatrelvir/ritonavir with the following: siponimod, cladribine and modafinil For those patients taking oral or intravenous methylprednisolone discuss the steroid dose with the MS neurology team as nirmatrelvir/ritonavir may increase corticosteroid levels. Myasthenia Gravis <ul style="list-style-type: none"> This includes muscle specific kinase (MUSK) myasthenia and the Lambert-Eaton Myasthenic Syndrome (LEMS). There are anecdotal reports of myasthenia gravis worsening in association with nirmatrelvir/ritonavir There are no known specific drug interactions. Myasthenia can be aggravated by COVID-19 and COVID-19 vaccination and requires close monitoring given the risk of bulbar and respiratory failure. Motor Neurone Disease (MND) <ul style="list-style-type: none"> Discuss patients on quinine with an MND physician Levels of riluzole treatment may be increased by nirmatrelvir/ritonavir and should be temporarily suspended following discussion with an MND physician. Huntington's Disease <ul style="list-style-type: none"> In addition to the medicines listed in the SPS guidance, avoid concurrent use of nirmatrelvir/ritonavir with the following: primidone, tetrabenazine and trihexyphenidyl
Immunology	Considering commonly prescribed medications in immunology, there are no issues with concomitant immunoglobulin replacement therapy and nirmatrelvir/ritonavir and nMABs. Patients should be informed by specialist clinicians and clinical/patient networks to maintain a list of all medications including those prescribed in hospital. Patients may be taking prophylactic antimicrobials - please refer to the list of contraindicated medications in the SPS guidance for further reference.
Obstetrics and gynaecology	It is recommended that CMDU staff liaise with their Maternity COVID Champion, or dedicated clinician when assessing a pregnant patient with COVID. Please ensure that a full drug history and past medical history is taken as other specialists may also need to be involved, for example renal or transplant teams. Use of ritonavir may reduce the efficacy of combined hormonal contraceptives. Patients using combined hormonal contraceptives should be advised to use an effective alternative contraceptive method or an additional barrier method of contraception during treatment and until after one complete menstrual cycle after stopping nirmatrelvir/ritonavir.
Paediatrics	For paediatric/adolescent patients (aged 12-17 year inclusive), paediatric multidisciplinary team (MDT) assessment should be used to determine clinical capacity to benefit from treatment.

Clinical Guide: Specialty advice for 'highest-risk' cohorts

Specialty-specific advice on the management of patients within each of the highest-risk cohorts (particularly around the use of nirmatrelvir/ritonavir) may be found in the table below. Contact your local specialist team for further guidance on issues not covered by this advice.

Cohort	Advice/guidance
IMID	<p>Factors to be considered in IMID patients:</p> <ul style="list-style-type: none"> • Consistent with existing guidance on management of COVID-19 in patients with IMID, patients should temporarily suspend their conventional DMARD(s), biologic and/or JAK inhibitor until the course of antiviral treatment has been completed and symptoms of COVID-19 are improving (this will usually be between 1-3 weeks). For most patients this will not require specific contact with the specialty team. • Do not stop or decrease corticosteroids • Swallowing difficulties may preclude the use of oral antivirals e.g. in patients with dysphagia due to myositis, oesophageal dysmotility due to scleroderma/systemic sclerosis because of the size of the tablets (approximately 2cm long) • Do not delay antiviral treatment pending specialist advice <p>The following links on speciality websites may be useful:</p> <ul style="list-style-type: none"> • The British Society for Rheumatology website • COVID-19 guidance British Society for Rheumatology • COVID-19 Guidance & Advice - The British Society of Gastroenterology (bsg.org.uk) • British Thoracic Society website: https://www.brit-thoracic.org.uk/covid-19/ • British Association of Dermatologists Advice for Dermatology HCPs during COVID-19 pandemic: https://www.bad.org.uk/healthcare-professionals/covid-19
HIV/AIDS	<ul style="list-style-type: none"> • It is recommended that each CMDU has details of their local HIV specialist service (both specialist HIV pharmacist and HIV physician) to discuss individuals where advice is needed. Specialty arrangements for referral to HIV specialist advice may be regional in some areas. • The majority of individuals living with HIV and referred to CMDUs for nirmatrelvir/ritonavir treatment should be managed in accordance with the guidance without the need for referral to the specialist centre. There are no antiretroviral treatment (ART) regimens that are a contraindication to nirmatrelvir/ritonavir treatment. No dose adjustment of any ART agent including ritonavir or cobicistat is needed. Interactions with other generalist co-medications prescribed should be assessed according to guidance including by reference to the Liverpool Covid drug interaction website. • Some individuals living with HIV do not disclose their HIV status to their GPs. It is therefore good practice to enquire of individuals during triage if they have any other medical conditions or take any other medications not managed directly by their GP. • CD4 counts are no longer routinely monitored in those with virological suppression and previous counts above 350 cells/mm³. These individuals will generally be assessed as not meeting the immunosuppression criteria although some patients may still meet the criteria that take account of other demographic factors and co-morbidities. We suggest using an age threshold of 55 years or older as an appropriate indicator for treatment in these circumstances as this was the inclusion criteria used in clinical studies.
Down's syndrome ¹	<ul style="list-style-type: none"> • The following issues should be given due consideration when assessing a patient for treatment with a suitable antiviral or nMAB: <ul style="list-style-type: none"> • The individual is likely to have impaired ability to understand the information given and they may be more likely to have hearing and communication difficulties • There is significant potential for co-existence of significant health conditions • There is a need for a corroborated and detailed collateral medical and drug history from an informant • Mental capacity assessment is an essential part of the assessment/triage process in these individuals • Other people cannot consent for an individual's treatment unless they are legally permitted to do so • In patients judged not to have capacity, a process of best interests decision-making should be pursued. • A person with Down's syndrome may be more likely to be taking medications that are contra-indicated or which may lead to interactions with nirmatrelvir/ritonavir e.g.: <ul style="list-style-type: none"> • For heart conditions and high blood pressure • Antipsychotics, antidepressants, anxiolytics • Anticonvulsants (anti-epileptics) • Statins • Nirmatrelvir/ritonavir tablets are relatively large (8-9mm diameter) and should not be crushed. Patients with swallowing difficulties will need support to ensure these are taken safely. • Contact the hospital learning disability liaison nurse (if available) or the local specialist learning disability service for clinical advice around psychotropic medications and the implication of contraindications and potential interactions

¹This advice may also apply to individuals with other chromosomal abnormalities affecting immune competence.